// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Reduced Action Precision and Biased Learning in Substance Users When Solving the Explore-Exploit Dilemma: An Active Inference Modelling Approach

Ryan Smith - Society of Biological Psychiatry (SOBP) , 2021

Therapeutic Area

Disease

Drug/Treatment

Substance Abuse

Substance Use Disorders

N/A

Glutamate, Glutathione and Intracortical Myelination in Schizophrenia

Min Tae M. Park - Society of Biological Psychiatry (SOBP) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Schizophrenia

glutathione

Stability and Controllability of Mood in Depression

Jolanda Malamud - Society of Biological Psychiatry (SOBP) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Depression

N/A

Meningeal γδ T Cells Impact on Cognition in Health and Disease

Helena Brigas - Society of Biological Psychiatry (SOBP) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Dopamine Enhances Model-Free Credit Assignment Through Boosting of Retrospective Model-Based Inference

Lorenz Deserno - Society of Biological Psychiatry (SOBP) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Dopamine hydrochloride

Computational Modelling of EEG and fMRI Paradigms Reveals a Consistent Loss of Pyramidal Cell Synaptic Gain in Schizophrenia

Rick Adams - Society of Biological Psychiatry (SOBP) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Schizophrenia

N/A

Are Metacognitive Biases in Anxious-Depression Ameliorated Following Successful Depression Treatment? A Longitudinal, Observational Study

Celine Fox - Society of Biological Psychiatry (SOBP) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Depression

N/A

Mechanisms of Rumination Change in Adolescent Depression (RuMeChange)

Scott Langenecker - Society of Biological Psychiatry (SOBP) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Depression

N/A

Childhood Maltreatment History is Linked to Abnormal Brain Structure in Conduct Disorder

Marlene Staginnus - Society of Biological Psychiatry (SOBP) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Cortical Projection Topography Across Thalamus Reflects Large-Scale Brain Organization

Amber Howell - Society of Biological Psychiatry (SOBP) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Cortical and Subcortical Neuroanatomical Signatures of Schizotypy in 2,952 Individuals Assessed in a Worldwide ENIGMA Study

Matthias Kirschner - Society of Biological Psychiatry (SOBP) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Rapid Dysregulation of Pre- and Post-Synaptic Glutamatergic Components in the Entorhinal Cortex by Amyloid-β Peptide Involves NMDA Receptor Hyperactivation

Olayemi Olajide - Society of Biological Psychiatry (SOBP) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

Modeling Effort-Based Decision Making in Major Depressive Disorder Following Ketamine Administration

Christina Wusinich - Society of Biological Psychiatry (SOBP) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Depression

Ketamine Injection

Probing the Minimally Delayed Ocular-Motor Response Task in Psychosis

Brooke S. Jackson - Society of Biological Psychiatry (SOBP) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Adherence to a Six-Week Study of Wearable Digital Mood and Cognitive Assessments in Depression: Qualitative Insights

Caroline Skirrow - Society of Biological Psychiatry (SOBP) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Depression

N/A

Nevertheless, She Persisted: Reward Responsivity and Effort Expenditure Contribute to Persistence on a Difficult Cognitive Task in Individuals With Mood and Anxiety Symptoms, With Identifiable Neural Correlates

Arielle Keller - Society of Biological Psychiatry (SOBP) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Anxiety

N/A

OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE

Andreas Reiter - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Mastocytosis

Midostaurin

VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY

Othman Al-Sawaf - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Obinutuzumab

ASSOCIATION BETWEEN HEMOGLOBIN LEVELS AND END-ORGAN DAMAGE IN SICKLE CELL DISEASE: A RETROSPECTIVE LINKED PRIMARY AND SECONDARY CARE DATABASE ANALYSIS IN ENGLAND

Paul Telfer - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

N/A

A BASELINE AUDIT OF THE USE A VALIDATED PSYCHOMETRIC TOOL (ASCQ-ME) TO ASSESS THE UNMET PSYCHOLOGICAL NEEDS OF A 2021 COHORT OF PATIENTS LIVING WITH SICKLE CELL

Kyle Kelleher - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxycarbamide

Copyright © 2026. QuantiNova All rights reserved